Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 15, 2019

Primary Completion Date

November 30, 2021

Study Completion Date

December 31, 2021

Conditions

Parkinson Disease

Interventions

DRUG

NBTX-001

Active drug group will receive 6 doses of NBTX-001 given three times a week.

DRUG

Standard of Care

Placebo group will receive reconstituted air given three times a week.

Trial Locations (2)

RECRUITING

Institute of Addictology, Moscow

RECRUITING

MONIKI, Moscow